학술논문
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study
Document Type
article
Author
Viani, Rolando M; Ruel, Theodore; Alvero, Carmelita; Fenton, Terry; Acosta, Edward P; Hazra, Rohan; Townley, Ellen; Palumbo, Paul; Buchanan, Ann M; Vavro, Cindy; Singh, Rajendra; Graham, Bobbie; Anthony, Patricia; George, Kathleen; Wiznia, Andrew; Heckman, Barbara; Popson, Stephanie; Sise, Thucuma; Hergott, Katelyn; Myers, Kathryn; Rodriguez, Carina A; Emmanuel, Patricia J; Casey, Denise; Wara, Diane; Tilton, Nicole; Aziz, Mariam; McNichols, Maureen; Logan, Latania; Sirisanthana, Virat; Aurpibul, Linda; Kosachunhanan, Nataporn; Jensen, Jennifer; Williams, Ruth; Qureshi, Tarannum; Dobroszycki, Joanna; Huh, Heesun; Reinoso, Francisco; Rana, Sohail; Houston, Patricia; Mengistab, Mulu; Burchett, Sandra K; Karthas, Nancy; Kneut, Catherine
Source
Journal of the Pediatric Infectious Diseases Society. 9(2)
Subject
Language
Abstract
BackgroundP1093 is an ongoing phase I/II multicenter open-label study of dolutegravir plus an optimized background regimen in age-defined pediatric cohorts; here we report the long-term safety and virologic efficacy outcomes for the oldest cohort.MethodsThe study enrolled human immunodeficiency virus type 1 (HIV-1)-infected treatment-experienced adolescents aged 12 to